Antibodies against CD9 have utility in characterisation of acute leukaemias and in some cases AML and for Fn studies on platelets
| Inventor | Institute |
|---|---|
| Jacqueline Cordell | University of Oxford |
| Cat. #: | 151347 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Developmental biology;Immunology;Stem cell biology;Tissue-specific biology |
| Application: | FACS ; IHC |
| Target: | CD9 |
| Reactivity: | Human |
| Clone: | P1/33/2 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | CD9 Molecule; Cell Growth-Inhibiting Gene 2 Protein; Motility Related Protein-1; Leukocyte Antigen MIC3; CD9 Antigen (P24); Tetraspanin-29; 5H9 Antigen; TSPAN29; MRP-1 |
|---|---|
| Product description: | CD9 antigen is a glycoprotein expressed on the surface of developing B lymphocytes, platelets, monocytes, eosinophils, basophil, stimulated T lymphocytes and neurons and glial cells in the peripheral nervous system. CD9 mediates platelet aggregation and activation via FcgRIIa. It may play a role in cell migration.Antibodies against CD9 have utility in characterisation of acute leukaemias and in some cases AML and for functional studies on platelets |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Acute lymphoblastic leukaemia cells |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | CD9 antigen is a glycoprotein expressed on the surface of developing B lymphocytes, platelets, monocytes, eosinophils, basophil, stimulated T lymphocytes and neurons and glial cells in the peripheral nervous system. CD9 mediates platelet aggregation and activation via FcgRIIa. It may play a role in cell migration.Antibodies against CD9 have utility in characterisation of acute leukaemias and in some cases AML and for Fn studies on platelets |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Taghizadeh et al. 2010. PLoS One. 5(12):e15183. PMID: 21203549. CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. Jennings et al. 1993. CD9 cluster workshop report: cell surface binding and Fn analysis. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 2, Oxford University Press, Oxford, New York and Tokyo, p 1249-51 |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.